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Background
Effective treatment of malaria relies mostly on Artemisin
Combination Therapy (ACT), which consists of the
administration of an Artemisinin (ART) derivative in
conjunction with a chemically unrelated anti-malarial,
such as Mefloquine (MF). ACTs should reduce the
chances of a parasite carrying mutations conferring
resistance to both drugs [1]. However, parasites resistant
to the different components of the combination have
recently been reported. For instance, in Southeast Asia,
the appearance of parasites showing increased in vivo
tolerance to artesunate (ATN) [2,3] may undermine the
future efficacy of the ATN+MF combination.
We have previously selected stable resistance to ATN
in the rodent malaria parasite Plasmodium chabaudi [4].
ATN-resistant parasites showed a mutation on pcubp1
gene, coding fora deubiquitinating enzyme [5]. No
changes were found in thepcatp6 and and pcmdr1
genes [4].
In order to study the genetics of resistance to ACTs,
the ATN-resistant P.chabaudi clone was repeatedly sub-
inoculated into mice continuously treated with ATN +
MF. Upon reaching a certain level of resistance, para-
sites were cloned by limiting dilution. The parasites’
genetic background was investigated by SOLEXA whole
genome re-sequencing. The identified mutations were
confirmed by dideoxy sequencing real-time polymerase
chain reaction.
Results
Selection and cloning procedures originated five parasite
clones, of which only one, denoted AS-ATNMF-1, was
investigated. When compared to the ATN-resistant pro-
genitor, AS-ATNMF-1 is resistant to treatment with the
combination of both ATN+MF, as well as to each drug
separately.
AS-ATNMF-1 carries three distinctive mutations one
of which is a duplication of the mdr1 gene. The remain-
ing two mutations are SNPs in genes of unknown func-
tion and remain to be further investigated. No
differences were found in the coding sequences of
pcatp6 and pcubp1 when comparing AS-ATNMF-1 and
its progenitor.
Conclusions
This work provides strong evidence to support the pos-
sibility of the emergence of resistance to ACTs, even
when the two drugs of the combination are adminis-
tered simultaneously. Additionally, duplication of the
mdr1 g e n em a yp l a yar o l ei nm e d i a t i n gA T N+M F
resistance. However, the presence of other mutations
seems to be required for the expression of this
phenotype.
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